Vitaliy Виталий

Dr. Vitaliy Виталий


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
NGNariman Gadzhiev
Nariman Gadzhiev
VВVitaliy Виталий
Vitaliy Виталий
GRGennadii Rodionov
Gennadii Rodionov
Vineet GauharVineet Gauhar
Vineet Gauhar
GZGuohua Zeng
Guohua Zeng
Background: Different types of kidney stones are associated with distinct changes in urine chemistry. Methods: We assessed urinary parameters of 98 patients with calcium oxalate (CaOx) stones one month following endoscopic stone removal. The 24 h urine analysis encompassed the assessment of various parameters, including volume, sodium, chloride, sulfate, nitrate, fluoride, phosphate, calcium, potassium, magnesium, oxalate, uric acid, citrate, creatinine, and pH levels. Results: Hypocitraturia was the most prevalent urinary abnormality (61.2%, n = 63), followed by low urine volume (53%, n = 52) and hypercalciuria (50%, n = 49). We did not find any statistically significant differences between patients with whewellite (COM) (n = 69) and weddellite (COD) stones (n = 29) (p > 0.05). However, oxalate concentration was the only parameter with a statistically significant intergroup difference (p = 0.0297). Additionally, in univariate linear regression analysis, urinary phosphate levels ≥ 48.0 mmol/d showed a trend towards significance (OR 0.17, 95% CI 0.02–1.15, p = 0.0692), indicating that phosphaturia is associated with a significant increase in the odds ratio of COD stones. To further explore metabolic heterogeneity among stone formers, we conducted cluster analysis, which revealed three distinct metabolic subgroups. Cluster 1 was predominantly associated with COM stones (80.5%) and exhibited significantly higher urinary excretion of sodium, calcium, oxalate, phosphate, and uric acid compared to Cluster 2, which had a more balanced distribution of monohydrate and dihydrate stones. Conclusions: These findings suggest that a specific metabolic phenotype may be linked to COM stone formation, providing a framework for risk stratification and personalized prevention strategies in calcium oxalate stone formers.

26 December 2022 in Urology Herald
Verified
Journal Article
Open access
PDF file
NGNariman Gadzhiev
Nariman Gadzhiev
VВVitaliy Виталий
Vitaliy Виталий
AKAnna Kutina
Anna Kutina
IGI. A. Gorgotsky
I. A. Gorgotsky
AKA. I. Karpishchenko
A. I. Karpishchenko
DSD. D. Shkarupa
D. D. Shkarupa
Urolithiasis is a common multifactorial disease characterized by a high recurrence rate. This review is devoted to the urine pH as one of the main factors determining its lithogenic properties. It affects the excretion of lithogenic substances and stone formation inhibitors, the solubility, and the crystallization of substances involved in stone formation. The urine pH significantly affects the solubility of uric acid in urine, which decreases at a pH < 5.5. This explains the high incidence of uric acid concretions in patients with metabolic syndrome. Their insulin resistance leads to a decrease in the excretion of ammonium ions in the proximal tubules, leading to persistent urine acidification. The activity of many transport processes involved in the processing of calcium, citrates and phosphates is sensitive to changes in systemic or local pH. The data on the effect of urine pH on the solubility of calcium oxalate remain contradictory. At the same time, there is no doubt about the determining role of urine pH in the excretion of citrate, the most important stone formation inhibitor. The alkaline urine pH promotes the formation of concretions containing calcium phosphates. In conditions of constantly elevated urine pH in patients with persistent urease-producing urinary tract infection, a rapid growth of "infectious" concretions occurs. The review summarizes information on the causes of the decrease and increase in the urine pH, as well as the possibilities of medicinal and non-medicinal methods of modifying the urine pH during the prevention of stone formation recurrence.

20 April 2020 in Urology Herald
Verified
Journal Article
Open access
NGN. K. Gadjiev
N. K. Gadjiev
DGD. S. Gorelov
D. S. Gorelov
GAG. N. Akopyan
G. N. Akopyan
VВVitaliy Виталий
Vitaliy Виталий
AIA. O. Ivanov
A. O. Ivanov
SAS. H. Al-Shukri
S. H. Al-Shukri
Improvement of patients` knowledge about their disease is an important part of management of chronic diseases. One of the effective methods to increase the level of medical education of the population is to hold regular meetings with patients within the framework of «schools for patients». Urolithiasis is one of the most common urological diseases (3.5‒9.6% of the population). In addition to its high prevalence, Urolithiasis has a high recurrence rate (50‒75% over 5‒10 years). The most common prostate diseases are prostatitis, benign hyperplasia, and cancer. These diseases have a chronic course and require а long-term observation. Treatment of urolithiasis and prostatic diseases is one of the priority fields for the urology department of the Pavlov First St. Petersburg State Medical University. In addition to surgical treatment, the specialists of urology department take measures aimed at prevention of recurrence and complications of these diseases. Schools for patients with urolithiasis and prostate diseases are held every 3 months. The topics for discussion are chosen by the patients themselves. In addition to reports, patients undergo ultrasound of the kidneys, bladder and prostate, as well as consultations. Participation in schools of patients creates a conscious attitude to their disease, increases adherence to treatment and improves the prognosis of the disease. The distribution of such programs corresponds to the modern concept of preventive medicine and increases the efficiency of providing medical care to the population.

30 July 2025 in Urology Herald
Verified
Journal Article
Open access
PDF file
VВVitaliy Виталий
Vitaliy Виталий
ELElena Leonova
Elena Leonova
DGD. S. Gorelov
D. S. Gorelov
ISI. V. Semenyakin
I. V. Semenyakin
NGNariman Gadzhiev
Nariman Gadzhiev
Introduction. Cystinuria is a rare genetic disorder characterised by a markedly elevated concentration of cystine in the urine. Due to the low solubility of cystine in urine, patients with cystinuria face a lifelong increased risk of urinary stone formation. The exceptionally high recurrence rate necessitates the implementation of preventive measures. Given that most practising urologists have limited experience managing patients with cystine nephrolithiasis due to the disease’s rarity, the development of clinical guidelines for recurrence prevention represents a pressing need.Objective. To summarize the world literature on managing patients with cystine nephrolithiasis and present an algorithm for preventing the disease.Materials & methods. A systematic review of the literature in foreign and domestic scientific databases was conducted using the keywords: “cystine”, “cystine stones”, “cystinuria”, “cystine”, “cystine nephrolithiasis”, “cystinuria”. Two hundred forty-seven sources of literature were processed, 45 of which were included in the review.Results. Despite the currently irreversible genetic cause of cystinuria, the implementation of stone prevention strategies significantly reduces the recurrence rate of urolithiasis in affected patients. Prevention of cystine nephrolithiasis involves a multimodal, stepwise treatment approach. This includes reducing urinary cystine concentration through dietary modifications and increasing its solubility by alkalinising the urine, as well as the use of cystine-binding agents. This article presents a step-by-step algorithm for the prevention of cystine nephrolithiasis, based on the clinical course of the disease and objective parameters such as 24-hour cystine excretion and urinary pH.Conclusion. Current algorithms for preventing cystine nephrolithiasis, which combine both non-pharmacological and pharmacological strategies, are readily applicable in clinical practice and have been shown to effectively reduce the recurrence of this condition.

4 October 2020 in Urology Herald
Verified
Journal Article
Open access
PDF file
NGN. K. Gadjiev
N. K. Gadjiev
AVA. V. Vasilyeva
A. V. Vasilyeva
DZD. V. Zaytseva
D. V. Zaytseva
DGD. S. Gorelov
D. S. Gorelov
VВVitaliy Виталий
Vitaliy Виталий
SPS. B. Petrov
S. B. Petrov
Применение краткосрочного психотерапевтического вмешательства для улучшения приверженности терапии пациентов с мочекаменной болезнью

23 October 2026 in Cifra. Клиническая медицина
Verified
Journal Article
Open access
PDF file
ELElena Leonova
Elena Leonova
НГНариман Гаджиев
Нариман Гаджиев
VВVitaliy Виталий
Vitaliy Виталий
ОКОлег Кириллов
Олег Кириллов
ARAnna Romanovich
Anna Romanovich
JSJulia V. Sopova
Julia V. Sopova
Цистинурия — наследственное заболевание, характеризующееся нарушением транспорта цистина и развитием рецидивирующего нефролитиаза. Представлен клинический и молекулярно-генетический анализ случая цистинурии у молодой женщины. Описание клинического случая: пациентка 24 лет, страдающая псориазом и мочекаменной болезнью с дебютом заболевания в возрасте 18 лет. В 2023 г., в возрасте 21 года, у пациентки были выявлены правосторонний гидронефроз и множественные конкременты чашечно-лоханочной системы правой почки. Было проведено этапное урологическое лечение: стентирование правого мочеточника в апреле 2023 г. и перкутанная нефролитолапаксия с лазерной литотрипсией в октябре 2023 г. В январе 2024 г., в возрасте 22 лет, было выполнено повторное перкутанное вмешательство на правой почке с достижением «stone-free» статуса. Анализ состава удаленных конкрементов показал содержание цистина 95–100%. Экскреция цистина с мочой варьировала от 267,98 до 1197,4 мг/сут. Молекулярно-генетическое исследование (панель генов нефролитиаза) выявило в гене SLC7A9 гетерозиготный патогенный вариант c.614dupA (p.Asn206GlufsTer3) и новый, ранее не описанный миссенс-вариант c.1328A>G (p.Ser379Gly), классифицированный как вариант с неопределенным клиническим значением (VUS).Диагноз цистинурии типа B подтвержден совокупностью клинических, биохимических и молекулярно-генетических данных. Выявление известного патогенного варианта и нового ранее не описанного варианта c.1328A>G (p.Ser379Gly), рассматриваемого как потенциально патогенный, но в настоящее время классифицированного как VUS, подчеркивает значение молекулярно-генетической диагностики для верификации цистинурии и необходимость дальнейших исследований редких генетических вариантов. Представленный случай также демонстрирует важность индивидуального междисциплинарного подхода к ведению пациентов с сопутствующей аутоиммунной патологией (псориазом).